|
|
 Previous Article | Table of Contents | Next Article 
Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by Secretory Leukocyte Protease Inhibitor Occurs Prior to Viral Reverse Transcription
Tessie B. McNeely,
Diane C. Shugars,
Mary Rosendahl,
Christina Tucker,
Stephen P. Eisenberg, and
Sharon M. Wahl
From the Laboratory of Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, MD; Department of Surgery, Duke University Medical Center, Durham, NC; and Amgen (Synergen) Inc, Boulder, CO.
Infection of monocytes with human immunodeficiency virus type 1Ba-L (HIV-1Ba-L ) is significantly inhibited by treatment with the serine protease inhibitor, secretory leukocyte protease inhibitor (SLPI). SLPI does not appear to act on virus directly, but rather the inhibitory activity is most likely due to interaction with the host cell. The current study was initiated to investigate how SLPI interacts with monocytes to inhibit infection. SLPI was found to bind to monocytes with high affinity to a single class of receptor sites (~7,000 receptors per monocyte, KD = 3.6 nmol/L). The putative SLPI receptor was identified as a surface protein with a molecular weight of 55 ± 5 kD. A well-characterized function of SLPI is inhibition of neutrophil elastase and cathepsin G. However, two SLPI mutants (or muteins) that contain single amino acid substitutions and exhibit greatly reduced protease inhibitory activity still bound to monocytes and retained anti-HIV-1 activity. SLPI consists of two domains, of which the C-terminal domain contains the protease inhibiting region. However, when tested independently, neither domain had potent anti-HIV-1 activity. SLPI binding neither prevented virus binding to monocytes nor attenuated the infectivity of any virus progeny that escaped inhibition by SLPI. A polymerase chain reaction (PCR)-based assay for newly generated viral DNA demonstrated that SLPI blocks at or before viral DNA synthesis. Therefore, it most likely inhibits a step of viral infection that occurs after virus binding but before reverse transcription. Taken together, the unique antiviral activity of SLPI, which may be independent of its previously characterized antiprotease activity, appears to reside in disruption of the viral infection process soon after virus binding.
Blood, Vol. 90 No. 3 (August 1), 1997:
pp. 1141-1149
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Fakioglu, S. S. Wilson, P. M. M. Mesquita, E. Hazrati, N. Cheshenko, J. A. Blaho, and B. C. Herold
Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism
J. Virol.,
October 1, 2008;
82(19):
9337 - 9344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Nishimura, H. Saiga, S. Sato, M. Okuyama, H. Kayama, H. Kuwata, S. Matsumoto, T. Nishida, Y. Sawa, S. Akira, et al.
Potent Antimycobacterial Activity of Mouse Secretory Leukocyte Protease Inhibitor
J. Immunol.,
March 15, 2008;
180(6):
4032 - 4039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Alvarez, J. Reading, D. F. L. King, M. Hayes, P. Easterbrook, F. Farzaneh, S. Ressler, F. Yang, D. Rowley, and A. Vyakarnam
WFDC1/ps20 Is a Novel Innate Immunomodulatory Signature Protein of Human Immunodeficiency Virus (HIV)-Permissive CD4+ CD45RO+ Memory T Cells That Promotes Infection by Upregulating CD54 Integrin Expression and Is Elevated in HIV Type 1 Infection
J. Virol.,
January 1, 2008;
82(1):
471 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Samsom, A. P. J. van der Marel, L. A. van Berkel, J. M. L. M. van Helvoort, Y. Simons-Oosterhuis, W. Jansen, M. Greuter, R. L. H. Nelissen, C. M. L. Meeuwisse, E. E. S. Nieuwenhuis, et al.
Secretory Leukoprotease Inhibitor in Mucosal Lymph Node Dendritic Cells Regulates the Threshold for Mucosal Tolerance
J. Immunol.,
November 15, 2007;
179(10):
6588 - 6595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Novak, B. A. Donoval, P. J. Graham, L. A. Boksa, G. Spear, R. C. Hershow, H. Y. Chen, and A. Landay
Cervicovaginal Levels of Lactoferrin, Secretory Leukocyte Protease Inhibitor, and RANTES and the Effects of Coexisting Vaginoses in Human Immunodeficiency Virus (HIV)-Seronegative Women with a High Risk of Heterosexual Acquisition of HIV Infection
Clin. Vaccine Immunol.,
September 1, 2007;
14(9):
1102 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Moutsopoulos, S. Nares, N. Nikitakis, Z. Rangel, J. Wen, P. Munson, J. Sauk, and S. M. Wahl
Tonsil Epithelial Factors May Influence Oropharyngeal Human Immunodeficiency Virus Transmission
Am. J. Pathol.,
August 1, 2007;
171(2):
571 - 579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Peng, T. Greenwell-Wild, S. Nares, W. Jin, K. J. Lei, Z. G. Rangel, P. J. Munson, and S. M. Wahl
Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression
Blood,
July 1, 2007;
110(1):
393 - 400.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Wahl, T. Greenwell-Wild, and N. Vazquez
HIV accomplices and adversaries in macrophage infection
J. Leukoc. Biol.,
November 1, 2006;
80(5):
973 - 983.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Kazmi, J. R. Naglik, S. P. Sweet, R. W. Evans, S. O'Shea, J. E. Banatvala, and S. J. Challacombe
Comparison of Human Immunodeficiency Virus Type 1-Specific Inhibitory Activities in Saliva and Other Human Mucosal Fluids
Clin. Vaccine Immunol.,
October 1, 2006;
13(10):
1111 - 1118.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.M. Moutsopoulos, T. Greenwell-Wild, and S.M. Wahl
Differential Mucosal Susceptibility in HIV-1 Transmission and Infection
Advances in Dental Research,
April 1, 2006;
19(1):
52 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.C. Herzberg, A. Weinberg, and S.M. Wahl
(C3) The Oral Epithelial Cell and First Encounters with HIV-1
Advances in Dental Research,
April 1, 2006;
19(1):
158 - 166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Taggart, S.-A. Cryan, S. Weldon, A. Gibbons, C. M. Greene, E. Kelly, T. B. Low, S. J. O'Neill, and N. G. McElvaney
Secretory leucoprotease inhibitor binds to NF-{kappa}B binding sites in monocytes and inhibits p65 binding
J. Exp. Med.,
December 19, 2005;
202(12):
1659 - 1668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Venkataraman, A. L. Cole, P. Svoboda, J. Pohl, and A. M. Cole
Cationic Polypeptides Are Required for Anti-HIV-1 Activity of Human Vaginal Fluid
J. Immunol.,
December 1, 2005;
175(11):
7560 - 7567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. K. Jana, L. R. Gray, and D. C. Shugars
Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity
J. Virol.,
May 15, 2005;
79(10):
6432 - 6440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Vazquez, T. Greenwell-Wild, N. J. Marinos, W. D. Swaim, S. Nares, D. E. Ott, U. Schubert, P. Henklein, J. M. Orenstein, M. B. Sporn, et al.
Human Immunodeficiency Virus Type 1-Induced Macrophage Gene Expression Includes the p21 Gene, a Target for Viral Regulation
J. Virol.,
April 1, 2005;
79(7):
4479 - 4491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Doumas, A. Kolokotronis, and P. Stefanopoulos
Anti-Inflammatory and Antimicrobial Roles of Secretory Leukocyte Protease Inhibitor
Infect. Immun.,
March 1, 2005;
73(3):
1271 - 1274.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ma, T. Greenwell-Wild, K. Lei, W. Jin, J. Swisher, N. Hardegen, C. T. Wild, and S. M. Wahl
Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection
J. Exp. Med.,
November 15, 2004;
200(10):
1337 - 1346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Cheshenko, M. J. Keller, V. MasCasullo, G. A. Jarvis, H. Cheng, M. John, J.-H. Li, K. Hogarty, R. A. Anderson, D. P. Waller, et al.
Candidate Topical Microbicides Bind Herpes Simplex Virus Glycoprotein B and Prevent Viral Entry and Cell-to-Cell Spread
Antimicrob. Agents Chemother.,
June 1, 2004;
48(6):
2025 - 2036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Greene, N. G. McElvaney, S. J. O'Neill, and C. C. Taggart
Secretory Leucoprotease Inhibitor Impairs Toll-Like Receptor 2- and 4-Mediated Responses in Monocytic Cells
Infect. Immun.,
June 1, 2004;
72(6):
3684 - 3687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Wahl, T. Greenwell-Wild, G. Peng, G. Ma, J. M. Orenstein, and N. Vazquez
Viral and host cofactors facilitate HIV-1 replication in macrophages
J. Leukoc. Biol.,
November 1, 2003;
74(5):
726 - 735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yoshida, R. Tanaka, T. Murakami, Y. Takahashi, Y. Koyanagi, M. Nakamura, M. Ito, N. Yamamoto, and Y. Tanaka
Induction of Protective Immune Responses against R5 Human Immunodeficiency Virus Type 1 (HIV-1) Infection in hu-PBL-SCID Mice by Intrasplenic Immunization with HIV-1-Pulsed Dendritic Cells: Possible Involvement of a Novel Factor of Human CD4+ T-Cell Origin
J. Virol.,
August 15, 2003;
77(16):
8719 - 8728.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Odaka, T. Mizuochi, J. Yang, and A. Ding
Murine Macrophages Produce Secretory Leukocyte Protease Inhibitor During Clearance of Apoptotic Cells: Implications for Resolution of the Inflammatory Response
J. Immunol.,
August 1, 2003;
171(3):
1507 - 1514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Devoogdt, G. Hassanzadeh Ghassabeh, J. Zhang, L. Brys, P. De Baetselier, and H. Revets
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells
PNAS,
May 13, 2003;
100(10):
5778 - 5782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keller, M. E. Klotman, and B. C. Herold
Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus
J. Antimicrob. Chemother.,
May 1, 2003;
51(5):
1099 - 1102.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Geiben-Lynn, N. Brown, B. D. Walker, and A. D. Luster
Purification of a Modified Form of Bovine Antithrombin III as an HIV-1 CD8+ T-cell Antiviral Factor
J. Biol. Chem.,
October 25, 2002;
277(44):
42352 - 42357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Rooney, G. M. Denning, B. P. Davis, D. M. Flaherty, J. A. Chiorini, and J. Zabner
Bronchoalveolar Fluid Is Not a Major Hindrance to Virus-Mediated Gene Therapy in Cystic Fibrosis
J. Virol.,
September 11, 2002;
76(20):
10437 - 10443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Taggart, C. M. Greene, N. G. McElvaney, and S. O'Neill
Secretory Leucoprotease Inhibitor Prevents Lipopolysaccharide-induced Ikappa Balpha Degradation without Affecting Phosphorylation or Ubiquitination
J. Biol. Chem.,
September 6, 2002;
277(37):
33648 - 33653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zhang, R. C. M. Simmen, F. J. Michel, G. Zhao, D. Vale-Cruz, and F. A. Simmen
Secretory Leukocyte Protease Inhibitor Mediates Proliferation of Human Endometrial Epithelial Cells by Positive and Negative Regulation of Growth-associated Genes
J. Biol. Chem.,
August 9, 2002;
277(33):
29999 - 30009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L Dreyfuss and W. W Fawzi
Micronutrients and vertical transmission of HIV-1
Am. J. Clinical Nutrition,
June 1, 2002;
75(6):
959 - 970.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. SHAPIRO, G. B. POTT, and A. H. RALSTON
Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1
FASEB J,
January 1, 2001;
15(1):
115 - 122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ikuta, S. Suzuki, H. Horikoshi, T. Mukai, and R. B. Luftig
Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis
Microbiol. Mol. Biol. Rev.,
December 1, 2000;
64(4):
725 - 745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Wahl, T. Greenwell-Wild, H. Hale-Donze, N. Moutsopoulos, and J. M. Orenstein
Permissive factors for HIV-1 infection of macrophages
J. Leukoc. Biol.,
September 1, 2000;
68(3):
303 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kikuchi, T. Abe, M. Yaekashiwa, Y. Tominaga, H. Mitsuhashi, K. Satoh, T. Nakamura, and T. Nukiwa
Secretory Leukoprotease Inhibitor Augments Hepatocyte Growth Factor Production in Human Lung Fibroblasts
Am. J. Respir. Cell Mol. Biol.,
September 1, 2000;
23(3):
364 - 370.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. Moriuchi, M. Moriuchi, and A. S. Fauci
Cathepsin G, a Neutrophil-Derived Serine Protease, Increases Susceptibility of Macrophages to Acute Human Immunodeficiency Virus Type 1 Infection
J. Virol.,
August 1, 2000;
74(15):
6849 - 6855.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Maticic, M. Poljak, B. Kramar, J. Tomazic, L. Vidmar, B. Zakotnik, and U. Skaleric
Proviral HIV-1 DNA in Gingival Crevicular Fluid of HIV-1-infected Patients in Various Stages of HIV Disease
Journal of Dental Research,
July 1, 2000;
79(7):
1496 - 1501.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Hocini, P. Becquart, H. Bouhlal, H. Adle-Biassette, M. D. Kazatchkine, and L. Belec
Secretory Leukocyte Protease Inhibitor Inhibits Infection of Monocytes and Lymphocytes with Human Immunodeficiency Virus Type 1 but Does Not Interfere with Transcytosis of Cell-Associated Virus across Tight Epithelial Barriers
Clin. Vaccine Immunol.,
May 1, 2000;
7(3):
515 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Mulligan, A. B. Lentsch, M. Huber-Lang, R.-F. Guo, V. Sarma, C. D. Wright, T. R. Ulich, and P. A. Ward
Anti-Inflammatory Effects of Mutant Forms of Secretory Leukocyte Protease Inhibitor
Am. J. Pathol.,
March 1, 2000;
156(3):
1033 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. King, H. O.D. Critchley, and R. W. Kelly
Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role
Mol. Hum. Reprod.,
February 1, 2000;
6(2):
191 - 196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Semba, N. Kumwenda, T. E. Taha, D. R. Hoover, T. C. Quinn, Y. Lan, L. Mtimavalye, R. Broadhead, P. G. Miotti, L. van der Hoeven, et al.
Mastitis and Immunological Factors in Breast Milk of Human Immunodeficiency Virus-infected Women
J Hum Lact,
December 1, 1999;
15(4):
301 - 306.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Konopka, N. Shine, E. Pretzer, and N. Duzgunes
Secretory Leukocyte Protease Inhibitor (SLPI): Oxidation of SLPI Does Not Explain Its Variable Anti-HIV Activity
Journal of Dental Research,
December 1, 1999;
78(12):
1773 - 1776.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. A. M. A. Baqui, T. F. Meiller, and W. A. Falkler Jr.
Enhanced Secretory Leukocyte Protease Inhibitor in Human Immunodeficiency Virus Type 1-Infected Patients
Clin. Vaccine Immunol.,
November 1, 1999;
6(6):
808 - 811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ding, N. Thieblemont, J. Zhu, F. Jin, J. Zhang, and S. Wright
Secretory Leukocyte Protease Inhibitor Interferes with Uptake of Lipopolysaccharide by Macrophages
Infect. Immun.,
September 1, 1999;
67(9):
4485 - 4489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-y. Song, L. Zeng, W. Jin, J. Thompson, D. E. Mizel, K.-j. Lei, R.C. Billinghurst, A. R. Poole, and S. M. Wahl
Secretory Leukocyte Protease Inhibitor Suppresses the Inflammation and Joint Damage of Bacterial Cell Wall-Induced Arthritis
J. Exp. Med.,
August 16, 1999;
190(4):
535 - 542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. AGERBERTH, J. GRUNEWALD, E. CASTAÑOS-VELEZ, B. OLSSON, H. JÖRNVALL, H. WIGZELL, A. EKLUND, and G. H. GUDMUNDSSON
Antibacterial Components in Bronchoalveolar Lavage Fluid from Healthy Individuals and Sarcoidosis Patients
Am. J. Respir. Crit. Care Med.,
July 1, 1999;
160(1):
283 - 290.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Baron, J. Poast, and M. W. Cloyd
Why Is HIV Rarely Transmitted by Oral Secretions?: Saliva Can Disrupt Orally Shed, Infected Leukocytes
Arch Intern Med,
February 8, 1999;
159(3):
303 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. N. Fichorova and D. J. Anderson
Differential Expression of Immunobiological Mediators by Immortalized Human Cervical and Vaginal Epithelial Cells
Biol Reprod,
February 1, 1999;
60(2):
508 - 514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Lentsch, J. A. Jordan, B. J. Czermak, K. M. Diehl, E. M. Younkin, V. Sarma, and P. A. Ward
Inhibition of NF-{kappa}B Activation and Augmentation of I{kappa}Bß by Secretory Leukocyte Protease Inhibitor during Lung Inflammation
Am. J. Pathol.,
January 1, 1999;
154(1):
239 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Wahl, T. Greenwell-Wild, G. Peng, H. Hale-Donze, T. M. Doherty, D. Mizel, and J. M. Orenstein
Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression
PNAS,
October 13, 1998;
95(21):
12574 - 12579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Jin, C. F. Nathan, D. Radzioch, and A. Ding
Lipopolysaccharide-Related Stimuli Induce Expression of the Secretory Leukocyte Protease Inhibitor, a Macrophage-Derived Lipopolysaccharide Inhibitor
Infect. Immun.,
June 1, 1998;
66(6):
2447 - 2452.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
